Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: notyet who wrote (28527)	3/14/1999 8:30:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< actinic keratoses: Why does it take so long to publish the results? >> Just to throw up some stuff from the 1997 annual report so that readers can chew on it. Page 11, Paragraph 5: "Actinic Keratoses ... Targretin Gel is being evaluated in Phase IIa trials for the treatment of actinic keratoses." Page 26, Paragraph 4: "Ligand has an extensive Phase II clinical program in larger patient populations, including breast cancer, lung and prostate cancer, psoriasis and actinic keratoses." Page 8, Paragraph 1: "As Ligand's first products reach patients and the marketplace as early as late 1998, the revenue streams provided will help fund the larger trials needed for approval for Ligand's products directed towards diseases affecting larger patient populations, such as breast cancer, lung and prostate cancer, actinic keratoses and psoriasis." Sounds, to me, that Ligand had decided not to proceed any further with larger trials until 1999, when they expected revenues from product sales. That still doesn't explain, to me, why Ligand hasn't issued news releases on the results from these "smaller" trials. But, when Ligand issued these statements in their 1997 annual report, they already had some results from their smaller Phase II trials, which were in progress since 1996. So, it seems to me that Ligand had seen enough efficacy to plan for expanded trials "after" product approvals and much needed revenues in late 1998. OTOH, Ligand could've been hoping for better results from their Phase II trials during 1998. Any comments from Lake Ligand?